| Literature DB >> 30693592 |
Mikael Montelius1, Oscar Jalnefjord1,2, Johan Spetz1, Ola Nilsson3, Eva Forssell-Aronsson1, Maria Ljungberg1,2.
Abstract
Early non-invasive tumour therapy response assessment requires methods sensitive to biological and physiological tumour characteristics. The aim of this study was to find and evaluate magnetic resonance imaging (MRI) derived tumour tissue parameters that correlate with histological parameters and that reflect effects of radionuclide therapy. Mice bearing a subcutaneous human small-intestine neuroendocrine tumour were i.v. injected with 177 Lu-octreotate. MRI was performed (7 T Bruker Biospec) on different post-therapy intervals (1 and 13 days) using T2-weighted imaging, mapping of T2* and T1 relaxation time constants, as well as diffusion and dynamic contrast enhancement (DCE-MRI) techniques. After MRI, animals were killed and tumours excised. Four differently stained histological sections of the most central imaged tumour plane were digitized, and segmentation techniques were used to produce maps reflecting fibrotic and vascular density, apoptosis, and proliferation. Histological maps were aligned with MRI-derived parametric maps using landmark-based registration. Correlations and predictive power were evaluated using linear mixed-effects models and cross-validation, respectively. Several MR parameters showed statistically significant correlations with histological parameters. In particular, three DCE-MRI-derived parameters reflecting capillary function additionally showed high predictive power regarding apoptosis (2/3) and proliferation (1/3). T1 could be used to predict vascular density, and perfusion fraction derived from diffusion MRI could predict fibrotic density, although with lower predictive power. This work demonstrates the potential to use multiparametric MRI to retrieve important information on the tumour microenvironment after radiotherapy. The non-invasiveness of the method also allows longitudinal tumour tissue characterization. Further investigation is warranted to evaluate the parameters highlighted in this study longitudinally, in larger studies, and with additional histological methods.Entities:
Keywords: IVIM; cancer; functional MRI; histopathology; tumour therapy response
Mesh:
Substances:
Year: 2019 PMID: 30693592 PMCID: PMC6590232 DOI: 10.1002/nbm.4060
Source DB: PubMed Journal: NMR Biomed ISSN: 0952-3480 Impact factor: 4.044
MR examinations and pulse sequence parameters
| MR technique & pulse sequence | Pulse sequence parameters |
|---|---|
| IVIM‐DWI | 3 orthogonal gradient directions, gradient separation/duration: 9/4 ms |
| 12 | |
| 2D SE‐EPI | TR: 1500 ms, TE: 21 ms, number of averages/segments: 3/1 |
| Effective bandwidth ≈ 300 kHz | |
| Partial Fourier acceleration: 1.5 | |
| Pixel size: 3202 μm2, slice thickness: 1000 μm, slice gap: 500 μm | |
| Fat suppression: Frequency selective | |
| Scan time < 6 minutes | |
| T2*‐mapping | 10 echoes (TE): 5, 10, 15, … 50 ms |
| TR: 2000 ms, number of averages: 1, flip angle: 30° | |
| Multiple echo gradient echo (MGE) | Slice positions imported from IVIM‐DWI experiment |
| Pixel size: 1602 μm2, slice thickness: 1000 μm | |
| No fat suppression scan time < 4 minutes | |
| T1‐mapping | 7 TR: 13000, 9000, 4500, 2500, 1500, 750, 300 ms |
| TE: 24 ms, number of averages: 1, RARE factor: 4 | |
| 2D RARE (RAREVTR) | Refocusing flip angle: 180° |
| Pixel size: 2802 μm2, slice thickness: 1000 μm, single slice | |
| Slice positions imported from IVIM‐DWI experiment (central slice) | |
| No fat suppression | |
| Scan time < 10 minutes | |
| DCE‐MRI | Number of repetitions (dynamics): 100, temporal resolution: 4.2 s (varied slightly with FOV), contrast injection during sixth dynamic |
| 2D RARE | TR: 300 ms, TE: 24 ms, number of averages: 1, RARE factor: 4 |
| Partial Fourier acceleration: 1.5 | |
| Pixel size: 2802 μm2, slice thickness: 1000 μm, single slice | |
| Slice positions imported from IVIM‐DWI experiment (central slice) | |
| Fat suppression: Frequency selective | |
| Scan time < 8 minutes | |
| T2 weighted MRI | TR: 4190 ms, TE: 45 ms, number of averages: 2, RARE factor: 6 |
| Pixel size: (160 ± 50)2 μm2 (varied with FOV) | |
| 2D RARE | Slice thickness: 700 μm, no slice gap |
| Fat suppression: Frequency selective | |
| Scan time < 4 min |
MR parameter definitions
| Parameter | Description | |
|---|---|---|
|
| ||
|
| ||
|
| Diffusion coefficient | The tissue water diffusion coefficient |
|
| Pseudo diffusion coefficient | Perfusion related pseudo diffusion coefficient of incoherently flowing blood in the tissue |
|
| Perfusion fraction | Signal fraction of from incoherently flowing blood in the tissue |
|
| ||
|
| Apparent diffusion coefficient | The apparent diffusion coefficient, which includes effects from both diffusion and perfusion |
|
| ||
|
| ||
|
| T2* time | Transversal tissue relaxation time |
|
| ||
|
| T1 time | Longitudinal tissue relaxation time |
|
| ||
|
| ||
|
| Arrival time | Time after injection required for signal intensity to reach significant enhancement |
|
| Time of peak intensity | Time after injection required to reach maximum signal intensity |
|
| Time to peak | Time between |
|
| Relative, maximum signal enhancement |
Maximum signal intensity relative to baseline signal intensity: |
|
| Relative signal enhancement at 60 s |
Signal intensity at 60 s after injection relative to signal baseline intensity: |
|
| Signal enhancement ratio | Ratio of early (55 s) and late (300 s) relative signal enhancements |
|
| Contrast enhancement ratio |
Ratio of maximum signal intensity and baseline signal intensity: |
|
| Normalized area under the curve | Area under |
|
| Wash in | Maximum time derivative of |
|
| Wash out |
Maximum negative time derivative of |
|
| Brevity of enhancement | Time between the time points of |
|
| Initial slope | Average rate of signal enhancement between |
|
| Negative slope |
Average rate of signal decrease between |
Figure 1Obtaining digital histology images for alignment with the corresponding MR parameter maps. A) The dead animal is positioned for incision through skin and tumour, with scalpel cutting adjacent and parallel to the imaged tumour plane. B) Colour coding of the imaged tumour plane by tissue ink injections on the left, right and dorsal tumour borders. C) Digital photography of the divided and colour coded tumour, with indications of where the ink is visible. The plane of the surface facing the camera will be parallel to the microtome knife sweep plane. D) Glass microscopy slides with differently stained parallel sections are digitized using a slide scanner. E) The ink, preserved through the preparation and paraffin embedding procedure, is visible on the magnified portions of the digitized HE stained section, and can be used to recover the orientation of the histological sections for alignment with the MR images
Figure 2Histological images [(A‐D): HE, Ki67, CD31, MT] and MR images/parametric maps [(E‐H): IVIM‐DWI of b = 600 s/mm2, T1 map, T2* map, T2 weighted image] of tumour 2. The sequential image registration and data sampling procedure is as follows: 1) a tumour sub‐region (blue delineation on (A‐H)) is intermutually registered on the histological images, 2) the MR parameter maps of the same region are registered to the T2‐weighted image (H), 3) the final transformation linking all images to each other is established by registering a histological image also to the T2‐weighted image, and 4) a data sampling algorithm systematically extracts data from the entire registered region, before the next tumour sub‐region is manually registered for sampling. The yellow rectangle in (A‐H) shows the position of a first 250 × 250 μm2 sample in a registered tumour sub‐region. The average MR parameter values in the sample region are extracted from each parameter map, and the histological indices are calculated for the same position. The next sample is then taken adjacent to the first position, and the procedure is repeated until the entire registered region has been sampled. Enlargements of the sample position shown in (A‐D) are shown in (I‐L). enlargements were used to validate proper registration based on the tissue microscopic landmarks (e.g. region with low cell density on (I‐L)), as well as to reject samples where the magnification revealed histological artefacts, such as cracks or folds. Bars in (A) and (J) indicate 1.0 and 0.1 mm, respectively
Figure 3Tissue segmentation and calculation of histological indices. (A) HE stained histological section of tumour 4 with corresponding heat maps (K) of HEcount, Ki67count, MVD and FD. The orange square in (A) is magnified in (B), showing apoptotic regions (densely packed, dark stained nuclei of apoptotic cells, indicated by a yellow arrow), necrotic tissue (red arrow) and viable tumour, as verified by the corresponding Ki67 magnification (brown‐stained cells in (E)). the region in the blue rectangle in (B) is magnified in (C), where haematoxylin positive (dark purple) nuclear fragments of pyknotic (apoptotic) cells are visible. Another region of the same tumour, but stained with MT, is magnified in (G), with a black arrow indicating fibrotic tissue. The corresponding region stained with CD31 (i) reveals formations of blood vessels by the presence of endothelial cells (brown regions indicated with a green arrow). The right panel of the figure (d, f, h, j) shows the results from the segmentation used for index calculations, resulting in indices: HEcount = 395, Ki67count = 136, FD = 12.3% and MVD = 0.7% in b, f, h and j, respectively. Bars in (A, C, I) indicate 1.0, 0.01 and 0.1 mm, respectively
Figure 4Distribution of histological indices within each tumour (x‐axis) for the four evaluated stains. By visual inspection, the variation of histological indices within tumours appears greater than the variation between tumours, except for, e.g., MVD in tumour 4 and Ki67count in tumour 4 and 5. The indices of tumour 2 (harvested day 1 after therapy) show a distribution similar to the other tumours. Note the logarithmic scale for improved visualization of MVD and FD indices. The number of indices in the HEcount boxplots for tumour 1–5 are n = 209, 0, 222, 247, and 117, respectively. The corresponding numbers for Ki67count are: 210, 997, 222, 247 and 128; MVD: 213, 997, 222, 247 and 127; FD: 212, 996, 222, 247 and 125. The dot represents the median value, box edges represent 25th and 75th percentiles and whiskers represent 2.5th and 97.5th percentiles
Figure 5Predictive power of pairwise correlations for individual animals. The predictive power, defined as the mean squared error of 5‐fold cross validation normalized to the squared mean of the histological index, of models constructed from pairwise simple linear regression of MR parameters and histological indices. Data from each investigated tumour (animal) is shown separately
Figure 6Regression coefficients and p‐values for correlations found by the linear mixed‐effects model. The relation between MR parameters and histological indices, determined for the combined data from all tumour samples (n = 1821) is shown by the regression coefficient (upper plot). The corresponding p‐value is shown in the lower plot, where the vertical dashed line indicates the p = 0.05 level after adjustment for multiple comparisons. The p‐value for IS vs. Ki67count was 1.5e‐23. Note that interpretation of D* correlations should be avoided due to poor quality of data
Figure 7Dendrogram of the cluster analysis of the histological indices (upper), and MR derived parameters (lower)